Relmada Therapeutics, Inc.
RLMD · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $46 | $55 | $113 | $91 |
| G&A Expenses | $38 | $49 | $48 | $35 |
| SG&A Expenses | $38 | $49 | $48 | $35 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $84 | $104 | $161 | $126 |
| Operating Income | -$84 | -$104 | -$161 | -$126 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $4 | $5 | $4 | -$0 |
| Pre-Tax Income | -$80 | -$99 | -$157 | -$126 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$80 | -$99 | -$157 | -$126 |
| % Margin | – | – | – | – |
| EPS | -2.65 | -3.28 | -5.3 | -7.16 |
| % Growth | 19.2% | 38.1% | 26% | – |
| EPS Diluted | -2.65 | -3.28 | -5.3 | -7.16 |
| Weighted Avg Shares Out | 30 | 30 | 30 | 18 |
| Weighted Avg Shares Out Dil | 30 | 30 | 30 | 18 |
| Supplemental Information | – | – | – | – |
| Interest Income | $4 | $5 | $3 | $1 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $104 | $0 | $0 |
| EBITDA | -$84 | $5 | -$161 | -$126 |
| % Margin | – | – | – | – |